ResMed Inc. (RMD) Price Prediction 2026–2050

ResMed Inc. is a healthcare company that develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software, and offers a range of sleep diagnostics and therapy tools such as ApneaLink Air, NightOwl, and EasyCare Tx, along with AirView, myAir, and a connectivity module for device integration.

It also provides Brightree solutions, HEALTHCAREfirst services, MatrixCare EHR software, and MEDIFOX DAN software solutions to support home medical equipment, home health, and residential care providers. ResMed was founded in 1989 and is headquartered in San Diego, California. The description places the company in the Healthcare category and highlights its broad portfolio of devices and software for respiratory care.

ResMed operates internationally, delivering diagnostic devices, cloud-based monitoring, and software-enabled patient engagement to diagnose, treat, and manage sleep and breathing disorders across clinics, hospitals, and home settings. The combination of hardware, cloud services, and software platforms underpins its integrated approach to respiratory care.

As a diversified healthcare provider, ResMed combines medical devices with software ecosystems to support patient care pathways from diagnosis to ongoing therapy management. The business is anchored in its Sleep and Breathing Health and Residential Care Software segments, with a long-standing presence in the industry since its founding and a focus on improving patient engagement and compliance.

ResMed Inc. trades as RMD in the Healthcare sector. The current price is $208.05 with a market capitalization of $30.18B, and it holds a ranking position of 448. The current price and market position anchor a forecast that envisions a disciplined upward path in multiple future years.

Near term, the outlook unfolds through a sequence of rising average prices in the forecast years, with a bullish cadence beginning in 2027 and extending through the 2030s and beyond. Long-run targets show substantial upside, culminating in notable gains by 2040 and 2050.

The 30-day technical picture shows a neutral posture with near-term support and resistance levels that frame trading activity. The forecasted path suggests meaningful upside over the next several years, even as near-term momentum remains cautious.

Overall, ResMed presents a structured multi-year forecast with rising averages and high-end price targets, underscoring both the potential for substantial upside and the inherent uncertainty of long-horizon projections.

The multi-year forecast shows a steady ascent with the average price rising from $208.05 in 2026 to higher levels in subsequent years. The 2027 forecast sits at an average of $251.26 with a bullish sentiment and a 20.8% ROI. The path continues higher through 2028 ($254.41 avg), 2029 ($275.49 avg), and 2030 ($286.41 avg) with a 37.7% ROI, all labeled bullish.

Beyond 2030, the forecast envisions continued upside, climbing to $313.40 in 2031, $366.84 in 2032, $399.67 in 2033, $432.49 in 2034, and $451.64 in 2035, with increasingly strong bullish sentiment and higher ROI marks along the way (e.g., 50.6% in 2031, 76.3% in 2032, 92.1% in 2033, 107.9% in 2034, and 117.1% in 2035). The 2040 forecast shows an average of $658.02 with a high of $1,004.86 and a ROI of 216.3%, while the 2050 forecast projects an average of $1,123.99, a high of $1,839.31, and a ROI of 440.3%, all within a bullish framework.

These are estimates, not guarantees, and reflect a potential upside path under the stated assumptions. The forecast highlights meaningful long-term upside but also implies exposure to market and cyclical risk, so outcomes may differ from the presented ranges over time.